4/A: Palatin Technologies Director Alan W. Dunton Reports Acquisition of Shares and Stock Options

Director Alan W. Dunton reports acquisition of common stock and stock options in Palatin Technologies, with an amendment correcting the exercise price of the derivative security.

Summary

• Alan W. Dunton, a director of Palatin Technologies, reported acquiring 12,000 shares of common stock and 17,000 stock options on July 15, 2024.
• The common stock was acquired at a price of $0 per share, and the director now beneficially owns 42,294 shares.
• The stock options have an exercise price of $1.83 and vest on June 4, 2025, expiring on June 4, 2034.
• This Form 4/A is an amendment to a previous filing, correcting the conversion or exercise price of the derivative security to $1.83.
• The original grant of restricted share units and options was subject to certification by the Chief Financial Officer regarding the increase in shares reserved under the 2011 Stock Incentive Plan, which was completed on July 15, 2024.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The director's acquisition of shares and options could be seen as mildly positive, but the filing itself is primarily informational.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options and restricted share units is contingent on continued service as a director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies, and the reporting requirements are standardized by the SEC.
• The vesting schedules and option terms are typical for director compensation packages, aligning their interests with the long-term performance of the company.
• Comparable companies in the biotechnology sector also utilize stock options and restricted share units as part of their compensation strategy for directors and executives.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares as a positive sign of confidence in the company.
• Employees may see the grants as part of the company's overall compensation strategy.

Key Dates